Home › Targets › CD19
CD19 (18 companies · 86 programs)
Companies with an active program directed at CD19.
- AUCATZYL — Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia Approved
- AUCATZYL — Pediatric Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia Phase 2
- AUCATZYL — Diffuse Large B-Cell Lymphoma Phase 1
- AUCATZYL — Chronic Lymphocytic Leukemia Phase 1
- AUCATZYL — Follicular Lymphoma Phase 1
- AUCATZYL — Primary Central Nervous System Lymphoma Phase 1
- AUCATZYL — Systemic Lupus Erythematosus Phase 1
- AUCATZYL — Lupus Nephritis Phase 2
- AUCATZYL — Progressive Multiple Sclerosis Phase 1
- AUTO1/22 — Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia Phase 1
- AUTO8 — Relapsed/Refractory Multiple Myeloma Phase 1
- AUTO8 — Light Chain Amyloidosis Phase 1
- CNTY-308 — Systemic Lupus Erythematosus Preclinical
- CNTY-308 — Lupus Nephritis Preclinical
- CNTY-308 — Idiopathic Inflammatory Myopathy Preclinical
- CNTY-308 — Diffuse Cutaneous Systemic Sclerosis Preclinical
- CNTY-101 — Systemic Lupus Erythematosus Phase 1
- CNTY-101 — Lupus Nephritis Phase 1
- CNTY-101 — Idiopathic Inflammatory Myopathy Phase 1
- CNTY-101 — Diffuse Cutaneous Systemic Sclerosis Phase 1
- CNTY-308
- resecabtagene autoleucel — Systemic Lupus Erythematosus Phase 1
- resecabtagene autoleucel — Lupus Nephritis Phase 1
- resecabtagene autoleucel — Dermatomyositis Phase 1
- resecabtagene autoleucel — Immune-Mediated Necrotizing Myopathy Phase 1
- resecabtagene autoleucel — Systemic Sclerosis Phase 1
- resecabtagene autoleucel — Generalized Myasthenia Gravis Phase 1
- resecabtagene autoleucel — Pemphigus Vulgaris Phase 1
- resecabtagene autoleucel — Autoimmune Diseases Phase 1
- mivocabtagene autoleucel — Stiff Person Syndrome NDA Submitted
- mivocabtagene autoleucel — Generalized Myasthenia Gravis Phase 3
- mivocabtagene autoleucel — Progressive Multiple Sclerosis Phase 1
- mivocabtagene autoleucel — Rheumatoid Arthritis Phase 2
- mivocabtagene autoleucel — Lupus Nephritis Phase 1
- KYV-102 Phase 1
- KYV-201 Preclinical
- NKX019 — Lupus Nephritis Phase 1
- NKX019 — Primary Membranous Nephropathy Phase 1
- NKX019 — Systemic Sclerosis Phase 1
- NKX019 — Idiopathic Inflammatory Myopathy Phase 1
- NKX019 — ANCA-Associated Vasculitis Phase 1
- NKX019 — Systemic Lupus Erythematosus Phase 1
- NKX019 — Myasthenia Gravis Phase 1
- AlloNK — Rheumatoid Arthritis Phase 1
- AlloNK — Sjögren's Disease Phase 2
- AlloNK — Systemic Sclerosis Phase 2
- AlloNK — Idiopathic Inflammatory Myopathies Phase 2
- AlloNK — Systemic Lupus Erythematosus Phase 1
- AlloNK — Lupus Nephritis Phase 1
- XmAb657 — Idiopathic Inflammatory Myopathies Phase 1
- obexelimab — Relapsing Multiple Sclerosis Phase 2
- obexelimab — Immunoglobulin G4-Related Disease NDA Submitted
- obexelimab — Systemic Lupus Erythematosus Phase 2
- Monjuvi — Diffuse Large B-Cell Lymphoma Approved
- Monjuvi — Follicular Lymphoma Approved
- budoprutug — Primary Membranous Nephropathy Phase 2
- budoprutug — Immune Thrombocytopenia Phase 2
- budoprutug — Systemic Lupus Erythematosus Phase 1
- budoprutug — Systemic Lupus Erythematosus Phase 1
- budoprutug — Primary Membranous Nephropathy Phase 1
- ZYNLONTA — Diffuse Large B-Cell Lymphoma Approved
- ZYNLONTA — Marginal Zone Lymphoma Phase 2
- ZYNLONTA — Follicular Lymphoma Phase 2
- ZYNLONTA — Pediatric B-Cell Non-Hodgkin Lymphoma Phase 2
- cemacabtagene ansegedleucel — Large B-Cell Lymphoma Phase 2
- ALLO-329 — Systemic Lupus Erythematosus Phase 1
- ALLO-329 — Idiopathic Inflammatory Myopathies Phase 1
- ALLO-329 — Systemic Sclerosis Phase 1
- CLN-978 — Systemic Lupus Erythematosus Phase 1
- CLN-978 — Rheumatoid Arthritis Phase 1
- CLN-978 — Sjögren's Disease Phase 1
- CLN-978 — Lupus Nephritis Phase 2
- obexelimab — IgG4-Related Disease NDA Submitted
- obexelimab — Relapsing Multiple Sclerosis Phase 2
- obexelimab — Systemic Lupus Erythematosus Phase 2
- ZB014 Preclinical
- vispacabtagene regedleucel — Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Phase 1
- vispacabtagene regedleucel — Relapsed/Refractory Large B Cell Lymphoma Phase 1
- vispacabtagene regedleucel — Large B-Cell Lymphoma Phase 3
- CD19 t-haNK — Non-Hodgkin Lymphoma Phase 1
- CD19 t-haNK — Waldenström Macroglobulinemia Phase 1
- SG293 Preclinical
- SG293 — Non-Hodgkin Lymphoma Preclinical
- INB-619 — Systemic Lupus Erythematosus Preclinical
- azercabtagene zapreleucel — Progressive Multiple Sclerosis Phase 1
